FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 231 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer December 15, 2025 Melanoma Cells Are More Likely to Spread after a Stopover in... September 30, 2020 Snack Ideas and Tips for Better Sleep November 20, 2020 Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... August 5, 2021 Load more HOT NEWS Women in Science: Celebrating with our Women of Influence initiative Nurse Who Battled Cancer While In School Surprises Her Dad With... News digest – targeted radiation beam, precision medicine and our early... ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France
